[en] [en] OBJECTIVE: Approximately 15% to 20% of complete hydatidiform moles progress to post-molar gestational trophoblastic neoplasia. The presence of atypical extra-villous trophoblast foci, described in complete hydatidiform moles, has been associated with an increased risk of developing post-molar gestational trophoblastic neoplasia. The primary objective of this study was to evaluate the predictive value of atypical extra-villous trophoblast foci for treatment response in post-molar gestational trophoblastic neoplasia. Secondary objectives were to assess the clinical impact of these foci on disease characteristics, the International Federation of Gynecology and Obstetrics (FIGO) score, disease stage, and human chorionic gonadotropin (hCG) kinetics.
METHODS: A retrospective multi-center study was conducted by the Belgian Gestational Trophoblastic Diseases Registry (French-speaking center) between January 2017 and December 2022. All cases of complete hydatidiform mole were centrally reviewed by expert pathologists specialized in placental pathology from 3 university hospitals. Post-molar gestational trophoblastic neoplasia was diagnosed according to FIGO 2000 criteria. Clinical features were compared according to the presence or absence of atypical trophoblast foci.
RESULTS: Among 216 patients diagnosed with complete hydatidiform mole, 56 (26%) developed post-molar gestational trophoblastic neoplasia. Atypical extra-villous trophoblast foci were identified in 38 of 56 (68%) cases. Baseline demographic characteristics, including age, were comparable between the 2 groups. Patients with atypical foci more frequently had FIGO scores ≥6 (p =.044) and pulmonary metastases (18.4% vs 5.6%). All patients requiring multi-agent chemotherapy belonged to the atypical foci group (p =.073). Pre-treatment hCG nadir levels were higher, and hCG slopes steeper in the atypical group (p =.0027 and p =.0052).
CONCLUSIONS: Post-molar gestational trophoblastic neoplasia arising from complete hydatidiform moles with atypical extra-villous trophoblast foci is more frequently associated with an unfavorable prognosis and the need for multi-agent chemotherapy than disease arising from moles without atypical foci.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Schoenen, Sophie ; Université de Liège - ULiège > Département des sciences cliniques
Delbecque, Katty ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Marbaix, Etienne; Cliniques Universitaires Saint-Luc (UCL), University Hospital Saint-Luc, Department of Pathology, Brussels, Belgium
Noel, Jean-Christophe; Université Libre de Bruxelles, Erasme University Hospital, Department of Pathology, Brussels, Belgium
Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Seidel, Laurence ; Université de Liège - ULiège > Département des sciences de la santé publique
Van Rompuy, Anne-Sophie ; KU Leuven, University Hospitals Leuven, Leuven Cancer Institute, Department of Pathology, Leuven, Belgium
Van Nieuwenhuysen, Els; Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium, KU Leuven, University Hospitals Leuven, Leuven Cancer Institute, Department of Obstetrics and Gynecology, Gynecologic Oncology, Leuven, Belgium
Van Gorp, Toon ; Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium, KU Leuven, University Hospitals Leuven, Leuven Cancer Institute, Department of Obstetrics and Gynecology, Gynecologic Oncology, Leuven, Belgium
Vergote, Ignace ; Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium, KU Leuven, University Hospitals Leuven, Leuven Cancer Institute, Department of Obstetrics and Gynecology, Gynecologic Oncology, Leuven, Belgium
Kridelka, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie-Obstétrique
Bolze, Pierre-Adrien; Université Lyon 1, Hospices Civils de Lyon, Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France
Goffin, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie-obstétrique, partim Gynécologie
Ngan HY, Bender H, Benedet JL, et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83(suppl 1):175-177. doi:10.1016/S0020-7292(03)90120-2
Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(suppl 1):86-93. doi:10.1002/ijgo.13877
Schoenen S, Delbecque K, Marbaix E, et al. Presence of atypical extravillous trophoblast foci is an independent predictor of the risk of progression to postmolar neoplasia. Am J Obstet Gynecol. 2025;233(4):303.e1-303.e9. doi:10.1016/j.ajog.2025.03.030, S0002-9378(25)00176-0
Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204(1):11-18. doi:10.1016/j.ajog.2010.06.072
FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105(1):3-4. doi:10.1016/j.ijgo.2008.12.015
Braga A, Paiva G, Cattai CJ, Elias KM, Horowitz NS, Berkowitz RS. Current chemotherapeutic options for the treatment of gestational trophoblastic disease. Expert Opin Pharmacother. 2023;24(2):245-258. doi:10.1080/14656566.2022.2150075
Prouvot C, Golfier F, Massardier J, et al. Efficacy and safety of second-line 5-day dactinomycin in case of methotrexate failure for gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2018;28(5):1038-1044. doi:10.1097/IGC.0000000000001248
Hoeijmakers YM, Sweep F, Lok C, Ottevanger PB. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study. BJOG. 2020;127(9):1139-1145. doi:10.1111/1471-0528.16198
Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer. 2012;107(11):1810-1814. doi:10.1038/bjc.2012.462
Parker VL, Winter MC, Tidy JA, et al. PREDICT-GTN 2: two-factor streamlined models match FIGO performance in gestational trophoblastic neoplasia. Gynecol Oncol. 2024;180:152-159. doi:10.1016/j.ygyno.2023.11.017
Vandewal A, Delbecque K, Van Rompuy AS, et al. Curative effect of second curettage for treatment of gestational trophoblastic disease - Results of the Belgian registry for gestational trophoblastic disease. Eur J Obstet Gynecol Reprod Biol. 2021;257:95-99. doi:10.1016/j.ejogrb.2020.12.001
Coopmans L, Larsson A, Joneborg U, Lok C, van Trommel N. Surgical management of gestational trophoblastic disease. Gynecol Obstet Investig. 2024;89(3):214-229. doi:10.1159/000534065
Schoenen S, Delbecque K, Van Rompuy AS, et al. Importance of pathological review of gestational trophoblastic diseases: results of the Belgian Gestational Trophoblastic Diseases Registry. Int J Gynecol Cancer. 2022;32(6):740-745. doi:10.1136/ijgc-2021-003312
Lok C, van Trommel N, Braicu EI, et al. Practical guidelines for the treatment of gestational trophoblastic disease: collaboration of the European organisation for the treatment of trophoblastic disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-gynecologic cancer InterGroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD). JCO. 2025;43(18):2119-2128. doi:10.1200/JCO-24-02326
Braga A, Paiva G, Ghorani E, et al. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol. 2021;22(8):1188-1198. doi:10.1016/S1470-2045(21)00262-X
Maesta I, Nitecki R, Horowitz NS, et al. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center experience. Gynecol Oncol. 2018;148(1):161-167. doi:10.1016/j.ygyno.2017.10.028
Kizaki S, Hashimoto K, Matsui H, Usui H, Shozu M. Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2015;139(3):429-432. doi:10.1016/j.ygyno.2015.10.007
Strohl AE, Lurain JR. Postmolar choriocarcinoma: an independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2016;141(2):276-280. doi:10.1016/j.ygyno.2016.02.014
Ramirez LAC, Maesta I, Bianconi MI, et al. Apresentacao clinica, resultados do tratamento e fatores relacionados a resistencia em mulheres sul-americanas com neoplasia trofoblastica gestacional pos-molar de baixo risco. Rev Bras Ginecol Obstet. 2022;44(8):746-754. doi:10.1055/s-0042-1748974
Chapman-Davis E, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol. 2012;125(3):572-575. doi:10.1016/j.ygyno.2012.03.039
You B, Pollet-Villard M, Fronton L, et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol. 2010;21(8):1643-1650. doi:10.1093/annonc/mdq033
Kemin L, Mengpei Z, Rutie Y. Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6. Front Oncol. 2022;12:1035170. doi:10.3389/fonc.2022.1035170
Deligdisch L, Driscoll SG, Goldstein DP. Gestational trophoblastic neoplasms: morphologic correlates of therapeutic response. Am J Obstet Gynecol. 1978;130(7):801-806. doi:10.1016/0002-9378(78)90012-1
Zeng X, An R, Guo R, Li H. Hypermethylated RASAL1’s promotive role in chemoresistance and tumorigenesis of choriocarcinoma was regulated by TET2 but not DNMTs. BMC Cancer. 2024;24(1):977. doi:10.1186/s12885-024-12758-w
Bolze PA, Lopez J, Allias F, et al. Transcriptomic and immunohistochemical approaches identify HLA-G as a predictive biomarker of gestational choriocarcinoma resistance to monochemotherapy. Gynecol Oncol. 2020;158(3):785-793. doi:10.1016/j.ygyno.2020.05.042
